{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:53:34Z","timestamp":1793933614470,"version":"4.8.0"},"reference-count":173,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    While autologous CAR T-cell therapies have revolutionized the treatment of hematologic malignancies, their widespread application is hindered by manufacturing complexities, high costs, and limited efficacy against solid tumors due to antigen heterogeneity and the TME. Moreover, the logistical burden of bespoke patient-specific manufacturing restricts global scalability. In response, the immunotherapy landscape is pivoting toward \u201coff-the-shelf\u201d allogeneic therapies derived from innate and innate-like effectors. This review provides a comprehensive analysis of four emerging platforms: CAR-NK cells, CAR-NKT cells, \u03b3\u03b4 T cells, and CAR-M. Unlike conventional \u03b1\u03b2 T cells, these lineages utilize MHC-independent mechanisms to recognize stress-induced ligands or lipid antigens, inherently minimizing the risk of GvHD while enabling standardized, batched manufacturing. We critically examine the diverse manufacturing paradigms, contrasting the scalability of iPSC-derived sources with the accessibility of umbilical cord blood products. Furthermore, we detail advanced engineering strategies designed to overcome the lineage-specific limitations revealed by early trials\u2014specifically, \u201carmoring\u201d constructs with IL-15 to boost\n                    <jats:italic>in vivo<\/jats:italic>\n                    persistence and metabolic reprogramming to sustain function within the TME. Finally, we synthesize emerging clinical evidence which confirms the favorable safety profile of these allogeneic approaches but highlights persistent bottlenecks: limited durability of response, cryopreservation-induced loss of viability, and batch-to-batch variability. We conclude that unlocking the full potential of innate CAR therapies requires a dual focus on harmonizing manufacturing controls and developing next-generation engineering logic to ensure durable control of solid tumors.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1691743","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:40:32Z","timestamp":1767940832000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["From innate-like to innate: the next wave of off-the-shelf CAR immunotherapies"],"prefix":"10.3389","volume":"16","author":[{"given":"Ying","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueru","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300213","article-title":"CAR T-cell immunotherapy in minority patients with lymphoma","volume":"3","author":"Ghilardi","year":"2024","journal-title":"NEJM Evid"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2118899","article-title":"CAR T-cell therapy for large B-cell lymphoma\u2014who, when, and how","volume":"386","author":"Roschewski","year":"2022","journal-title":"N Engl J Med Mass Med Soc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-025-01062-y","article-title":"CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges","volume":"22","author":"Abken","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-025-01924-1","article-title":"A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer","volume":"20","author":"Zhao","year":"2025","journal-title":"Nat Nanotechnol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2024.1492552","article-title":"Chimeric antigen receptor T-cell therapy in autoimmune diseases","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"122556","DOI":"10.1016\/j.lfs.2024.122556","article-title":"CAR T treatment beyond cancer: Hope for immunomodulatory therapy of non-cancerous diseases","volume":"344","author":"Yang","year":"2024","journal-title":"Life Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.06.008","article-title":"IL-18 revives dysfunctional CAR-T cells","volume":"11","author":"Li","year":"2025","journal-title":"Trends Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"J\u00f8rgensen","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02524-8","article-title":"iPSC-derived CD19 CAR NK cells for relapsed or refractory lymphoma","volume":"405","author":"Shapiro","year":"2025","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11060-024-04876-z","article-title":"CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws","volume":"171","author":"Sabahi","year":"2025","journal-title":"J Neurooncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"103883","DOI":"10.1016\/j.autrev.2025.103883","article-title":"The role of \u03b3\u03b4 T cells and CAR-\u03b3\u03b4 T cell therapy in autoimmune diseases","volume":"24","author":"Wang","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.3146","article-title":"Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset","volume":"97","author":"Cooper","year":"2001","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science (80-)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.10.6072","article-title":"Negative regulation of NK cell activities by inhibitory receptor CD94\/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection","volume":"173","author":"Jinushi","year":"2004","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.44","article-title":"Defining the nature of human \u03b3\u03b4 T cells: a biographical sketch of the highly empathetic","volume":"10","author":"Kalyan","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell aloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science (80-)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1561174","article-title":"New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies","volume":"16","author":"Rassek","year":"2025","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/imr.12793","article-title":"Cellular therapy: Adoptive immunotherapy with expanded natural killer cells","volume":"290","author":"Lee","year":"2019","journal-title":"Immunol Rev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"101889","DOI":"10.1016\/j.xcrm.2024.101889","article-title":"CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3892\/mmr.2025.13587","article-title":"IPSC-derived NK cells for immunotherapy and therapeutic perspective","volume":"32","author":"Wei","year":"2025","journal-title":"Mol Med Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887866","article-title":"Custom CARs: leveraging the adaptability of allogeneic CAR therapies to address current challenges in relapsed\/refractory DLBCL","volume":"13","author":"Jeyakumar","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","article-title":"Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions","volume":"10","author":"Zhong","year":"2024","journal-title":"Cell Death Discov"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2018.07.007","article-title":"Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy","volume-title":"Cell Stem Cell","author":"Siegler","year":"2018"},{"key":"B34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s13287-024-03871-5","article-title":"Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34+ cells and PD-L1 CAR-modified UCB-CD34+-derived NK cells in killing target cells and restoration of the anti-tumor function of PD-1-high exhausted T Cells","volume":"15","author":"Ghaedrahmati","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"117024","DOI":"10.1016\/j.biopha.2024.117024","article-title":"CAR-NK cell therapy in AML: current treatment, challenges, and advantage","volume":"177","author":"Bahramloo","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-022-00660-2","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia","volume":"12","author":"Albinger","year":"2022","journal-title":"Blood Cancer J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/hum.2017.157","article-title":"Optimization of human NK cell manufacturing: fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells","volume":"28","author":"Kloss","year":"2017","journal-title":"Hum Gene Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"10508","DOI":"10.3390\/ijms241310508","article-title":"Generation and functional characterization of anti-CD19 chimeric antigen receptor-natural killer cells from human induced pluripotent stem cells","volume":"24","author":"Klaihmon","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell Malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5562630","DOI":"10.1155\/2021\/5562630","article-title":"Selective cytotoxicity of single and dual anti-CD19 and anti-CD138 chimeric antigen receptor-natural killer cells against hematologic Malignancies","volume":"2021","author":"Luanpitpong","year":"2021","journal-title":"J Immunol Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12967-025-06432-3","article-title":"Engineering CD5-targeting CAR-NK cells from peripheral blood for the treatment of CD5-positive hematological Malignancies","volume":"23","author":"Lin","year":"2025","journal-title":"J Transl Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab182","article-title":"Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice","volume":"24","author":"Chuntova","year":"2022","journal-title":"Neuro Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/cancers17050731","article-title":"Targeting HER2-positive solid tumors with CAR NK cells: CD44 expression is a critical modulator of HER2-specific CAR NK cell efficacy","volume":"17","author":"Gergely","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145706","article-title":"Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas","volume":"14","author":"Zuo","year":"2023","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00262-024-03808-0","article-title":"Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model","volume":"73","author":"Tachi","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"115973","DOI":"10.1016\/j.celrep.2025.115973","article-title":"CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients","volume":"44","author":"Cook","year":"2025","journal-title":"Cell Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0096","article-title":"CD28 costimulation augments CAR signaling in NK cells via the LCK\/CD3\u03b6\/ZAP70 signaling axis","volume":"14","author":"Acharya","year":"2024","journal-title":"Cancer Discov"},{"key":"B52","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12967-022-03626-x","article-title":"Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy","volume":"20","author":"Zhang","year":"2022","journal-title":"J Transl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2858","article-title":"Development and function of human innate immune cells in a humanized mouse model","volume":"32","author":"Rongvaux","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00246-w","article-title":"Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany","volume":"28","author":"Albinger","year":"2021","journal-title":"Gene Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"115123","DOI":"10.1016\/j.biopha.2023.115123","article-title":"IPSC-derived CAR-NK cells for cancer immunotherapy","volume":"165","author":"Lin","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01015-z","article-title":"The landscape of CAR-engineered innate immune cells for cancer immunotherapy","volume":"6","author":"Tsahouridis","year":"2025","journal-title":"Nat Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2015.9","article-title":"Natural killer cell memory in infection, inflammation and cancer","volume":"16","author":"Cerwenka","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-419283","article-title":"Cytokine activation induces human memory-like NK cells","volume":"120","author":"Romee","year":"2012","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-1002","article-title":"A fusion protein complex that combines IL-12, IL-15, and IL-18 signaling to induce memory-like NK cells for cancer immunotherapy","volume":"9","author":"Becker-Hapak","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1038\/s41467-024-47574-0","article-title":"Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation","volume":"15","author":"Berjis","year":"2024","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12943-024-02151-3","article-title":"CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside","volume":"23","author":"Zhu","year":"2024","journal-title":"Mol Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e003894","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J Immunother Cance"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17186","article-title":"Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity","volume":"193","author":"Rafei","year":"2021","journal-title":"Br J Haematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967956.37234.fb","article-title":"S261: first in human data of NKX019, an allogeneic car NK for the treatment of relapsed\/refractory (R\/R) B-cell Malignancies","volume":"7","author":"Dickinson","year":"2023","journal-title":"HemaSphere"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-023-00711-w","article-title":"NK cell therapeutics for hematologic Malignancies: From potential to fruition","volume":"18","author":"Fetzko","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","article-title":"Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial","volume":"14","author":"Huang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11033-025-11163-1","article-title":"Generation of the augmented IL-15-secreting anti-HER2 chimeric antigen receptor (CAR)-NK cells: an encouraging immunotherapeutic tool","volume":"53","author":"Darvishvand","year":"2026","journal-title":"Mol Biol Rep"},{"key":"B74","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-142750","article-title":"FT576: multi-specific off-the-shelf CAR-NK cell therapy engineered for enhanced persistence, avoidance of self-fratricide and optimized mab combination therapy to prevent antigenic escape and elicit a deep and durable response in multiple myeloma","volume":"136","author":"Goodridge","year":"2020","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166994","article-title":"Interim phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed\/refractory multiple myeloma","volume":"140","author":"Dhakal","year":"2022","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1182\/blood-2020-141606","article-title":"Initial clinical activity of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed\/refractory B-cell lymphoma","volume":"136","author":"Bachanova","year":"2020","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nri3369","article-title":"Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions","volume":"13","author":"Brennan","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601399","article-title":"Type II NKT cells and their emerging role in health and disease","volume":"198","author":"Dhodapkar","year":"2017","journal-title":"J Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"103488","DOI":"10.1016\/j.retram.2024.103488","article-title":"CAR-iNKT cell therapy: mechanisms, advantages, and challenges","volume":"73","author":"Wang","year":"2025","journal-title":"Curr Res Transl Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The biology of NKT cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12248","article-title":"The peripheral differentiation of human natural killer T cells","volume":"97","author":"Liu","year":"2019","journal-title":"Immunol Cell Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200940278","article-title":"NKG2D performs two functions in invariant NKT cells: Direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d","volume":"41","author":"Kuylenstierna","year":"2011","journal-title":"Eur J Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.1.1","article-title":"Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- \u03b1\/\u03b2 T cells demonstrates preferential use of several V\u03b2 genes and an invariant TCR \u03b1 chain","volume":"178","author":"Porcelli","year":"1993","journal-title":"J Exp Med"},{"key":"B84","volume-title":"Cytotoxic Invariant Natural Killer T Cells as Potential Effectors for Cancer Immunotherapy","author":"de Amat Herbozo","year":"2024"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031462","article-title":"Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2","volume":"199","author":"Metelitsa","year":"2004","journal-title":"J Exp Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"eabn6563","DOI":"10.1126\/sciimmunol.abn6563","article-title":"TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells","volume":"8","author":"Delfanti","year":"2022","journal-title":"Sci Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00830-0","article-title":"CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms","volume":"5","author":"Zhou","year":"2024","journal-title":"Nat Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0114","article-title":"A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer","volume":"12","author":"Motohashi","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0600","article-title":"Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: A phase I clinical trial","volume":"23","author":"Exley","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.04.005","article-title":"Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy","volume":"32","author":"Li","year":"2024","journal-title":"Mol Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41467-025-56270-6","article-title":"Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid Malignancies","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-541235","article-title":"Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy","volume":"124","author":"Heczey","year":"2014","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83476","article-title":"CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo","volume":"126","author":"Tian","year":"2016","journal-title":"J Clin Invest"},{"key":"B94","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40164-024-00553-z","article-title":"Efficacy of NKG2D CAR-T cells with IL-15\/IL-15R\u03b1 signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder","volume":"13","author":"Mai","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2490","article-title":"Shared and distinct transcriptional programs underlie the hybrid nature of iNKT cells","volume":"14","author":"Cohen","year":"2013","journal-title":"Nat Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41467-023-44310-y","article-title":"IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity","volume":"15","author":"Landoni","year":"2024","journal-title":"Nat Commun"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1329","article-title":"Allogeneic CAR invariant natural killer T cells exert potent antitumor effects through host CD8 T-cell cross-priming","volume":"27","author":"Simonetta","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.03.001","article-title":"The clinical landscape of CAR-engineered unconventional T cells","volume":"11","author":"Li","year":"2025","journal-title":"Trends Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"115587","DOI":"10.1016\/j.celrep.2025.115587","article-title":"Single-cell transcriptomic profiling reveals diversity in human iNKT cells across hematologic tissues","volume":"44","author":"Jayasinghe","year":"2025","journal-title":"Cell Rep"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01061-8","article-title":"Off-the-shelf\u201d Allogeneic CAR cell therapy\u2014Neglected HvG effect","volume":"24","author":"An","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molimm.2020.12.010","article-title":"Using agonists for iNKT cells in cancer therapy","volume":"130","author":"Painter","year":"2021","journal-title":"Mol Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1182\/blood-2021-149712","article-title":"Allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B-cell Malignancies: an interim analysis","volume":"138","author":"Ramos","year":"2021","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00722-1","article-title":"The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.104","article-title":"Cytotoxic and regulatory properties of circulating V\u03b41+ \u03b3\u03b4 T cells: a new player on the cell therapy field","volume":"22","author":"Siegers","year":"2014","journal-title":"Mol Ther"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/nri2781","article-title":"Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity","volume":"10","author":"Bonneville","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00452-4","article-title":"\u03b3\u03b4 T cells in tissue physiology and surveillance","volume":"21","author":"Ribot","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.4.2144","article-title":"Activation of V\u03b39V\u03b42 T cells by NKG2D","volume":"175","author":"Rincon-Orozco","year":"2005","journal-title":"J Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00607","article-title":"Tumor-infiltrating \u03b3\u03b4 T lymphocytes: Pathogenic role, clinical significance, and differential programing in the tumor microenvironment","volume":"5","author":"Lo Presti","year":"2014","journal-title":"Front Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/nri3904","article-title":"\u03b3\u03b4 T cells in cancer","volume":"15","author":"Silva-Santos","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor \u03b3\u03b4 cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J Exp Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1182\/blood-2011-02-339135","article-title":"Differentiation of human peripheral blood V\u03b41+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells","volume":"118","author":"Correia","year":"2011","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-752162","article-title":"The potential role of \u03b3\u03b4 T cells after allogeneic HCT for leukemia","volume":"131","author":"Handgretinger","year":"2018","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1080\/14653240802419328","article-title":"Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy","volume":"10","author":"Kondo","year":"2008","journal-title":"Cytotherapy"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.293","article-title":"Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours","volume":"105","author":"Nicol","year":"2011","journal-title":"Br J Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1021-7","article-title":"Phase I\/II study of adoptive transfer of \u03b3\u03b4 T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma","volume":"60","author":"Kobayashi","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05077.x","article-title":"Human \u03b3\u03b4 T cells as mediators of chimaeric-receptor redirected anti-tumour immunity","volume":"126","author":"Rischer","year":"2004","journal-title":"Br J Haematol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e1373","DOI":"10.1002\/cti2.1373","article-title":"Allogeneic CD20-targeted \u03b3\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models","volume":"11","author":"Nishimoto","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-0195","article-title":"B7-H3-targeted CAR-V\u03b41T cells exhibit potent broad-spectrum activity against solid tumors","volume":"84","author":"Jiang","year":"2024","journal-title":"Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03260-y","article-title":"CAR \u03b3\u03b4 T cells for cancer immunotherapy. Is the field more yellow than green","volume":"72","author":"Ganapathy","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B124","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imr.12923","article-title":"Immune recognition of phosphoantigen-butyrophilin molecular complexes by \u03b3\u03b4 T cells","volume":"298","author":"Uldrich","year":"2020","journal-title":"Immunol Rev"},{"key":"B125","article-title":"Distinct pattern of human Vdelta1 gammadelta T cells recognizing MICA","volume":"2","author":"Li","year":"2005","journal-title":"Cell Mol Immunol"},{"key":"B126","first-page":"1554541","article-title":"Prospects for Gamma Delta T cells and chimeric antigen receptor Gamma Delta T cells in cancer immunotherapy","volume-title":"Front Immunol","author":"Wang","year":"2025"},{"key":"B127","doi-asserted-by":"publisher","first-page":"100470","DOI":"10.1016\/j.jbo.2023.100470","article-title":"Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis","volume":"39","author":"Lorange","year":"2023","journal-title":"J Bone Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"eabq7248","DOI":"10.1126\/science.abq7248","article-title":"Cancer immunotherapy by \u03b3\u03b4 T cells","volume":"386","author":"Hayday","year":"2024","journal-title":"Science (80-)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022992","article-title":"CD155\/PVR determines acute myeloid leukemia targeting by Delta One T cells","volume":"143","author":"Mensurado","year":"2024","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00690-0","article-title":"PD-1 defines a distinct, functional, tissue-adapted state in V\u03b41+ T cells with implications for cancer immunotherapy","volume":"5","author":"Davies","year":"2024","journal-title":"Nat Cancer"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1402-1","article-title":"Anti-metastatic potential of human V\u03b41+ \u03b3\u03b4 T cells in an orthotopic mouse xenograft model of colon carcinoma","volume":"62","author":"Devaud","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200268","article-title":"\u6709\u9644\u4ef6B7-CD28 costimulatory signals control the survival and proliferation of murine and human \u03b3\u03b4 T cells via IL-2 production","volume":"189","author":"Ribot","year":"2012","journal-title":"J Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242842","article-title":"4-1BB signal stimulates the activation, expansion, and effector functions of \u03b3\u03b4 T cells in mice and humans","volume":"43","author":"Lee","year":"2013","journal-title":"Eur J Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01198-y","article-title":"4-1BB-encoding CAR causes cell death via sequestration of the ubiquitin-modifying enzyme A20","volume":"21","author":"Dou","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1303119","article-title":"Human \u03b3\u03b4 Thymocytes Are Functionally Immature and Differentiate into Cytotoxic Type 1 Effector T Cells upon IL-2\/IL-15 Signaling","volume":"192","author":"Ribot","year":"2014","journal-title":"J Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1303343","article-title":"Type I IFNs and IL-18 regulate the antiviral response of primary human \u03b3\u03b4 T cells against dendritic cells infected with dengue virus","volume":"194","author":"Tsai","year":"2015","journal-title":"J Immunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.3390\/ijms25052631","article-title":"Chimeric antigen receptor T cell therapy for hepatocellular carcinoma: where do we stand","volume":"25","author":"Aggeletopoulou","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3495","article-title":"Arming V\u03b42 T cells with chimeric antigen receptors to combat cancer","volume":"30","author":"Thomas","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1200\/JCO.2022.40.16_suppl.7509","article-title":"A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (\u03b3\u03b4) T cells in adults with B-cell Malignancies","volume":"40","author":"Neelapu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.3390\/cancers16173098","article-title":"Developmental therapeutics in metastatic prostate cancer: new targets and new strategies","volume":"16","author":"Zhang","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2014.00636","article-title":"Clinical applications of gamma delta T cells with multivalent immunity","volume":"5","author":"Deniger","year":"2014","journal-title":"Front Immunol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"2451074","DOI":"10.1002\/eji.202451074","article-title":"The potential of \u03b3\u03b4 CAR and TRuC T cells: An unearthed treasure","volume":"54","author":"Schamel","year":"2024","journal-title":"Eur J Immunol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/nri1733","article-title":"Monocyte and macrophage heterogeneity","volume":"5","author":"Gordon","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-012418-012718","article-title":"Diversity, mechanisms, and significance of macrophage plasticity","volume":"15","author":"Locati","year":"2020","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"B146","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.immuni.2010.05.007","article-title":"Alternative activation of macrophages: mechanism and functions","volume":"32","author":"Gordon","year":"2010","journal-title":"Immunity"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J Clin Invest"},{"key":"B148","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s12672-024-01464-5","article-title":"The two-sided battlefield of tumour-associated macrophages in glioblastoma: unravelling their therapeutic potential","volume":"15","author":"Xiong","year":"2024","journal-title":"Discov Oncol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s41577-024-01086-6","article-title":"Lipid transfer from tumour-associated macrophages supports glioblastoma","volume":"24","author":"Minton","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-1075","article-title":"Targeting macrophages with CAR T cells delays solid tumor progression and enhances antitumor immunity","volume":"10","author":"Sanchez-Paulete","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01696-7","article-title":"CAR macrophages on a fast track to solid tumor therapy","volume":"25","author":"Abdin","year":"2024","journal-title":"Nat Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","article-title":"The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors","volume":"11","author":"Hadiloo","year":"2023","journal-title":"biomark Res"},{"key":"B154","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat Commun"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat Med"},{"key":"B156","doi-asserted-by":"publisher","first-page":"e007705","DOI":"10.1136\/jitc-2023-007705","article-title":"Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia","volume":"11","author":"Abdin","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.12.043","article-title":"Targeting macrophages in cancer immunotherapy: Frontiers and challenges","volume":"76","author":"Liu","year":"2025","journal-title":"J Adv Res"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-396-7_16","article-title":"Analysis of matrix metalloproteinase secretion by macrophages","volume":"531","author":"Elkington","year":"2009","journal-title":"Methods Mol Biol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1038\/s41467-025-59326-9","article-title":"CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation","volume":"16","author":"Chen","year":"2025","journal-title":"Nat Commun"},{"key":"B161","doi-asserted-by":"publisher","first-page":"e36688","DOI":"10.7554\/eLife.36688.022","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"Elife"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03490-8","article-title":"Chimeric antigen receptor macrophages activated through TLR4 or IFN-\u03b3 receptors suppress breast cancer growth by targeting VEGFR2","volume":"72","author":"Duan","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01220-3","article-title":"Silencing of SIRP\u03b1 enhances the antitumor efficacy of CAR-M in solid tumors","volume":"21","author":"Zhang","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","article-title":"CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond","volume":"12","author":"Lu","year":"2024","journal-title":"biomark Res"},{"key":"B166","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.3390\/cells11223692","article-title":"CAR-macrophages and CAR-T cells synergistically kill tumor cells in vitro","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"B167","first-page":"1144","article-title":"Designing chimeric antigen receptors for myeloid immune cells","volume":"11","author":"Buys","year":"2024","journal-title":"J Cancer Biol Res"},{"key":"B168","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.1038\/s41467-023-41470-9","article-title":"Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"B169","doi-asserted-by":"publisher","first-page":"eadg0654","DOI":"10.1126\/sciadv.adg0654","article-title":"Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy","volume":"9","author":"Chen","year":"2023","journal-title":"Sci Adv"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2022.12.012","article-title":"Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies","volume":"18","author":"Zhang","year":"2023","journal-title":"Stem Cell Rep"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.951","article-title":"951 A phase 1 first in human study of adenovirally transduced anti-HER2 CAR macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data","author":"Reiss","year":"2021","journal-title":"BMJ Specialist Journals"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.0315","article-title":"315 Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508","volume":"10","author":"Ball","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B173","doi-asserted-by":"publisher","first-page":"e011929","DOI":"10.1136\/jitc-2025-011929","article-title":"SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy","volume":"13","author":"Sullivan","year":"2025","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1691743\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:40:35Z","timestamp":1767940835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1691743\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":173,"alternative-id":["10.3389\/fimmu.2025.1691743"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1691743","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1691743"}}